Monthly Archives:

CCP Test Associated with Reductions in Treatment Burden

Scottsdale, Arizona—In combination with standard clinicopathologic parameters, the cell cycle progression (CCP) risk assessment score is a validated assay that provides an estimate of the risk of progression of prostate cancer–specific disease and mortality. PROCEDE-1000 is a large, clinically controlled, prospective registry designed to evaluate the impact of the CCP test toward personalization of treatment for prostate cancer. Neal Shore, ... Read More »

Phase II Trial Tests Benefit of Local Tumor Therapy

Scottsdale, Arizona—Systemic therapy is at the center of treatment for metastatic prostate cancer. Existing evidence has suggested that outcomes in men with advance disease may be improved with definitive treatment of the primary tumor (DTPT). Further, there is evidence that local therapy may alter disease biology as well as prevent symptomatic local progression. Thus, according to researchers, definitive treatment of ... Read More »

High-Resolution Diffusion–Weighted MRI Detects Low-Volume Tumors

Indian Wells, California—Multiparametric magnetic resonance imaging (MP-MRI) can be used to identify larger tumors in candidates for prostatectomy. However, according to Ali-Reza Sharif-Afshar, MD, and colleagues, not all tumors are visible on MP-MRI; many small tumors found in patients on active surveillance are below the limits of detection, creating a need to characterize the long-term natural history of low-volume tumors ... Read More »

Safety of HoLEP Not Affected by Participation of Trainees

Indian Wells, California—There is a steep learning curve associated with the use of Holmium Laser Enucleation of the Prostate (HoLEP). HoLEP is an established surgical treatment for benign prostatic hyperplasia (BPH); however, the need for new endoscopic skills required has made the widespread adoption slow. Haidar M. Abdul-Muhsin, MBChB, and colleagues recently conducted a study designed to systemically measure the ... Read More »